readthroughSign in
CompanyCRDFNasdaqSan Diego, CA

Cardiff Oncology

Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor.

SCHEDULE 13GNov 16Latest SEC filing
Nov 16Latest story